BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

BioNTech and Moderna, both mRNA vaccine pioneers during the pandemic, are now pivoting to cancer vaccines as COVID revenue declines. Moderna is favored due to stronger recent clinical progress, including positive phase 3 results for its personalized cancer vaccine intismeran autogene and FDA approval for mFLUSIVA flu vaccine. While BioNTech has a deep pipeline including pumitamig, it has yet to deliver comparable phase 3 wins. Moderna's $61.2 billion market cap reflects investor confidence in its near-term commercialization prospects versus BioNTech's $26 billion valuation.

09/03/2026, 5:30 PM • The Motley Fool

3 Stocks Whose Competitive Walls Tower Over Nvidia's

While Nvidia has built a strong competitive moat in AI chips, three healthcare stocks—Moderna, Intuitive Surgical, and Vertex Pharmaceuticals—possess even more formidable competitive advantages. Moderna leverages its mRNA expertise across vaccines and oncology; Intuitive Surgical dominates robotic surgery with high switching costs; and Vertex leads in cystic fibrosis treatment with a patent-protected pipeline extending to the late 2030s.

09/03/2026, 11:10 AM • The Motley Fool

Is BioNTech Stock a No-Brainer Buy on the Dip?

BioNTech stock has underperformed significantly, losing 70% over five years as COVID-19 vaccine sales declined. However, the company's mRNA platform is gaining renewed investor interest following Moderna and Merck's successful cancer vaccine trial. BioNTech's diverse pipeline of oncology candidates, including BNT113, BNT116, and pumitamig, could drive future growth, though clinical setbacks remain a risk. The stock appears somewhat attractive but is not a guaranteed buy given its $25.4B valuation and lack of consistent profitability.

09/02/2026, 3:10 PM • The Motley Fool

Stock Market Today, Sept. 1: Stocks Slide and Oil Surges Amid U.S.-Iran Tension

U.S. stock markets declined on September 1, 2026, as rising crude oil prices and Treasury yields pressured equities following escalating U.S.-Iran tensions. The S&P 500 fell 0.71%, the Dow dropped 0.79%, and the Nasdaq declined 1.03%, with technology stocks leading the selloff. Growth stocks underperformed value stocks, while oil surged 5%.

09/01/2026, 5:02 PM • The Motley Fool

Down More Than 30% From Its Peak, Is Now the Perfect Time to Buy Sandisk Stock?

Sandisk stock has fallen over 30% from its all-time high despite being the S&P 500's best performer this year with ~550% gains. The article argues this is a buying opportunity as supply-demand imbalances in NAND memory chips continue to drive price increases. With Wall Street expecting 142% revenue growth for fiscal 2027 and the stock trading at only 7x forward earnings compared to 30x at year-end, the author suggests the stock could double or quadruple if valuations normalize.

09/01/2026, 4:18 PM • The Motley Fool

VOO vs. RSP: If AI Stocks Get Too Concentrated, Here's Which One I'd Choose

The Vanguard S&P 500 ETF (VOO) has become heavily concentrated in mega-cap tech stocks, with its top 10 holdings accounting for nearly 40% of assets and surpassing dot-com bubble concentration levels. The Invesco S&P 500 Equal Weight ETF (RSP) offers an alternative by weighting all 500 S&P 500 stocks equally, reducing concentration risk. While VOO has delivered strong returns driven by AI enthusiasm, the author suggests switching to RSP if concentration exceeds 50% to protect against potential AI stock corrections.

08/30/2026, 6:24 AM • The Motley Fool

mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and More

The global mRNA therapeutics market (excluding COVID-19 applications) is projected to grow from USD 201 million in 2026 to USD 9.98 billion by 2035, with a 63% CAGR. Growth is driven by expanding oncology and rare disease pipelines, advances in lipid nanoparticle delivery, and strategic partnerships. However, challenges include tissue-selective delivery limitations, repeat-dose tolerability concerns, and regulatory complexities. Moderna and BioNTech dominate with approximately 70% of pipeline activity.

08/26/2026, 9:46 AM • GlobeNewswire

$7+ Billion mRNA Vaccines Market Outlook, 2035: Opportunities, Strategies, Challenges

The global mRNA vaccines market for non-COVID applications is projected to grow at a 109% compound annual growth rate from $9 million in 2026 to $7.04 billion by 2035. Market expansion is driven by advancing clinical pipelines, diversification into influenza, RSV, oncology and next-generation RNA technologies, with over 100 mRNA-based cancer candidates under investigation. Influenza is expected to become the leading indication by 2035, while North America remains the largest regional market.

08/26/2026, 9:44 AM • GlobeNewswire

Why Tempus AI Skyrocketed This Week

Tempus AI stock surged 39.5% this week following positive Phase 3 trial results from Merck and Moderna for a jointly developed mRNA cancer vaccine combined with Keytruda immunotherapy. The gains were driven by Tempus's pending acquisition of Personalis, which developed the genomic tumor-profiling technology central to the vaccine's development. Despite the rally, Tempus remains down roughly 10% over the past year.

08/23/2026, 7:15 AM • The Motley Fool

A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know

Nadja West, a director at Tempus AI, sold 3,000 shares for $161,700 on August 14 under a pre-established Rule 10b5-1 trading plan set up in May. Four days later, the stock rallied 24% following news that Moderna and Merck's cancer vaccine succeeded in late-stage trials. West retained 34,981 shares worth ~$1.8 million. The sale timing appears coincidental as it was scheduled months in advance, and the company reported strong Q2 results with 22% revenue growth and its first GAAP profit.

08/22/2026, 8:19 AM • The Motley Fool

Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade

Tempus AI's Chief Legal Officer Andrew Polovin sold 30,075 shares worth $1.5 million in a non-discretionary transaction to cover tax withholding obligations from RSU vesting. The sale occurred during a 75% stock rally driven by positive results from a Moderna-Merck cancer vaccine trial validating Tempus's genomic sequencing technology. The company reported 22% revenue growth to $382.5 million last quarter and achieved its first GAAP profit, though it remains unprofitable on a TTM basis with -$254.4 million net income.

08/22/2026, 8:05 AM • The Motley Fool

Breakfast News: A Conversation With Ionis CEO

Ionis Pharmaceuticals CEO Brett Monia discusses the company's progress in 2026, highlighting FDA approval for Tryngolza and upcoming results for Pelacarsen in heart disease treatment. The company targets cash flow break-even in 2028 and projects $7 billion in peak revenue from late-stage programs. With 13 neurology drugs in clinical trials, Ionis aims to establish itself as a leader in antisense technology beyond first-mover competitors.

08/22/2026, 7:30 AM • The Motley Fool

Why Moderna Stock Skyrocketed Today

Moderna and Merck announced positive Phase 3 clinical trial results for intismeran, an mRNA-based cancer therapy designed to activate anti-tumor immune responses in melanoma patients. The experimental treatment met its primary endpoint of recurrence-free survival when combined with Merck's Keytruda immunotherapy. The companies plan to present additional data and seek regulatory approval, positioning them to capture a larger share of the $275 billion global oncology market by 2030.

08/19/2026, 8:07 PM • The Motley Fool

Moderna and Merck Just Made History With the First mRNA Cancer Vaccine to Succeed in a Phase 3 Trial. Here's What That Means for Investors.

Moderna and Merck announced successful Phase 3 trial results for a personalized mRNA cancer vaccine combined with Merck's Keytruda immunotherapy. The treatment showed melanoma patients experienced longer periods before cancer recurrence and reduced spread compared to Keytruda alone. This marks the first Phase 3 success for mRNA cancer therapy and individualized neoantigen therapy, with both companies planning to present findings to regulators.

08/19/2026, 12:34 PM • The Motley Fool

Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other Players

The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, growing at a 7% CAGR. Market expansion is driven by rising public health awareness, an aging population, government immunization programs, and increased R&D investment. Quadrivalent and inactivated vaccines lead the market, while cell-based technologies and pediatric segments show fastest growth. Key players include GlaxoSmithKline, Pfizer, Sanofi, Moderna, and others.

08/07/2026, 5:54 AM • GlobeNewswire